COMMENT

Biologic sales forecast to pass innovative small molecule sales in next five years

The telemedicine community has rallied to provide support to patients in Ukraine

Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments

Supply Chain

CMO agreements need to go public, but ‘glib’ onshoring not the answer

A new report commissioned by the US Congress recommends that the FDA should make drug supply chain information public. Fiona Barry writes about the potential implications.

insight

Europe reports the highest prevalence of chronic cough

comment

Could vaccine hesitancy impact hearing disorders?

Biologic sales forecast to pass innovative small molecule sales in next five years

The telemedicine community has rallied to provide support to patients in Ukraine

Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments

06/01/2022 13:43:12
  • Home | Continuous manufacturing cautiously builds on hype
  • In this issue
  • CSafe Global
  • Contents
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • SHL Medical Company Insight
  • SHL Medical
  • WR Grace
  • Comment
  • CMO agreements need to go public, but ‘glib’ onshoring not the answer
  • Biologic sales forecast to pass innovative small molecule sales in next five yea
  • The telemedicine community has rallied to provide support to patients in Ukraine
  • Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments
  • BioLife Solutions
  • Mimotopes Company Insight
  • Mimotopes
  • In Depth
  • Continuous manufacturing builds on hype but adoption remains gradual
  • Can Relmada’s fast-acting pill for major depressive disorder compete in
  • Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compa
  • How ambitious are the emissions targets of pharma and biotech companies?
  • Should Covid-19 clinical trial plans still centre around EUAs?
  • BEA Technologies
  • Datwyler Company Insight
  • Datwyler
  • In Data
  • Top and emerging locations for M&A deals in the pharma industry
  • Deals relating to genomics increased in the pharma industry in H2 2021
  • Pharma industry companies are increasingly innovating in machine learning
  • Baxter
  • Events
  • Next issue